Atea Pharmaceuticals (AVIR) Share-based Compensation: 2018-2024
Historic Share-based Compensation for Atea Pharmaceuticals (AVIR) over the last 7 years, with Dec 2024 value amounting to $51.8 million.
- Atea Pharmaceuticals' Share-based Compensation rose 2.59% to $11.6 million in Q4 2022 from the same period last year, while for Dec 2022 it was $46.7 million, marking a year-over-year increase of 17.91%. This contributed to the annual value of $51.8 million for FY2024, which is 4.73% up from last year.
- Per Atea Pharmaceuticals' latest filing, its Share-based Compensation stood at $51.8 million for FY2024, which was up 4.73% from $49.4 million recorded in FY2023.
- Atea Pharmaceuticals' 5-year Share-based Compensation high stood at $51.8 million for FY2024, and its period low was $7.5 million during FY2020.
- For the 3-year period, Atea Pharmaceuticals' Share-based Compensation averaged around $49.3 million, with its median value being $49.4 million (2023).
- Data for Atea Pharmaceuticals' Share-based Compensation shows a peak YoY spiked of 1,095.03% (in 2020) over the last 5 years.
- Over the past 5 years, Atea Pharmaceuticals' Share-based Compensation (Yearly) stood at $7.5 million in 2020, then spiked by 431.33% to $39.6 million in 2021, then rose by 17.91% to $46.7 million in 2022, then increased by 5.80% to $49.4 million in 2023, then rose by 4.73% to $51.8 million in 2024.